🎉 M&A multiples are live!
Check it out!

TYK Medicines Valuation Multiples

Discover revenue and EBITDA valuation multiples for TYK Medicines and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

TYK Medicines Overview

About TYK Medicines

TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.


Founded

2017

HQ

Hong Kong
Employees

153

Financials

Last FY Revenue $14K

LTM EBITDA -$45.1M

EV

$989M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

TYK Medicines Financials

TYK Medicines has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$45.1M.

In the most recent fiscal year, TYK Medicines achieved revenue of $14K and an EBITDA of -$44.1M.

TYK Medicines expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See TYK Medicines valuation multiples based on analyst estimates

TYK Medicines P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue n/a XXX $14K XXX XXX XXX
Gross Profit n/a XXX $2K XXX XXX XXX
Gross Margin n/a XXX 13% XXX XXX XXX
EBITDA -$45.1M XXX -$44.1M XXX XXX XXX
EBITDA Margin n/a XXX -323394% XXX XXX XXX
EBIT -$50.8M XXX -$40.4M XXX XXX XXX
EBIT Margin n/a XXX -296073% XXX XXX XXX
Net Profit -$57.0M XXX -$49.3M XXX XXX XXX
Net Margin n/a XXX -361640% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

TYK Medicines Stock Performance

As of July 2, 2025, TYK Medicines's stock price is HKD 22 (or $3).

TYK Medicines has current market cap of HKD 8.0B (or $1.0B), and EV of HKD 7.8B (or $989M).

See TYK Medicines trading valuation data

TYK Medicines Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$989M $1.0B XXX XXX XXX XXX $-0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

TYK Medicines Valuation Multiples

As of July 2, 2025, TYK Medicines has market cap of $1.0B and EV of $989M.

TYK Medicines's trades at 72562.1x EV/Revenue multiple, and -22.4x EV/EBITDA.

Equity research analysts estimate TYK Medicines's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

TYK Medicines has a P/E ratio of -19.7x.

See valuation multiples for TYK Medicines and 12K+ public comps

TYK Medicines Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $1.0B XXX $1.0B XXX XXX XXX
EV (current) $989M XXX $989M XXX XXX XXX
EV/Revenue n/a XXX 72562.1x XXX XXX XXX
EV/EBITDA -24.0x XXX -22.4x XXX XXX XXX
EV/EBIT -21.3x XXX -24.5x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -19.7x XXX -20.8x XXX XXX XXX
EV/FCF -19.1x XXX -20.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get TYK Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

TYK Medicines Margins & Growth Rates

TYK Medicines's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.3M for the same period.

TYK Medicines's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

TYK Medicines's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for TYK Medicines and other 12K+ public comps

TYK Medicines Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX 7085% XXX XXX XXX
EBITDA Margin n/a XXX -323394% XXX XXX XXX
EBITDA Growth -31% XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $0K XXX XXX XXX
Opex per Employee XXX XXX $0.3M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 220043% XXX XXX XXX
Opex to Revenue XXX XXX 296086% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

TYK Medicines Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

TYK Medicines M&A and Investment Activity

TYK Medicines acquired  XXX companies to date.

Last acquisition by TYK Medicines was  XXXXXXXX, XXXXX XXXXX XXXXXX . TYK Medicines acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by TYK Medicines

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About TYK Medicines

When was TYK Medicines founded? TYK Medicines was founded in 2017.
Where is TYK Medicines headquartered? TYK Medicines is headquartered in Hong Kong.
How many employees does TYK Medicines have? As of today, TYK Medicines has 153 employees.
Is TYK Medicines publicy listed? Yes, TYK Medicines is a public company listed on HKG.
What is the stock symbol of TYK Medicines? TYK Medicines trades under 02410 ticker.
When did TYK Medicines go public? TYK Medicines went public in 2024.
Who are competitors of TYK Medicines? Similar companies to TYK Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of TYK Medicines? TYK Medicines's current market cap is $1.0B
Is TYK Medicines profitable? Yes, TYK Medicines is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of TYK Medicines? TYK Medicines's last 12 months EBITDA is -$45.1M.
What is the current EV/EBITDA multiple of TYK Medicines? Current EBITDA multiple of TYK Medicines is -24.0x.
What is the current FCF of TYK Medicines? TYK Medicines's last 12 months FCF is -$56.9M.
What is the current EV/FCF multiple of TYK Medicines? Current FCF multiple of TYK Medicines is -19.1x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.